Tandem Diabetes Care, Inc. (TNDM) — 分析摘要
Tandem Diabetes Care, Inc.(TNDM)的市值为1.11十亿美元,最近一年的营收同比增长了+7.9%。净利润率为-20.2%。当前市盈率为-11.8倍。
核心要点
- 营收同比变化+7.9%
- 净利润率-20.2%
- 市盈率-11.8倍
与SURGICAL & MEDICAL INSTRUMENTS & APPARATUS板块的其他公司相比,TNDM的营收增长为+7.9%,市盈率为-11.8倍。
Tandem Diabetes Care, Inc. (TNDM)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗,在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -10.2x — 盈利不足以覆盖利息支出
D/E 为 4.5x — 财务杠杆偏高
最新报表显示自由现金流为负。
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
行业
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
员工人数
2,500
总部
San Diego, CA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。